Skip to main content

Table 4 Factors associated with the incidence of the first confirmed malaria event (n = 25) in the 1117 HIV-infected children included in the pWADA cohort. Abidjan May-August 2012

From: Effect of cotrimoxazole prophylaxis on the incidence of malaria in HIV-infected children in 2012, in Abidjan, Côte d’Ivoire: a prospective cohort study

  N n Univariate analysis Adjusted analysis
IRR (95 % IC) p-value aIRR (95 % CI) p-value
Antiretroviral therapy (ART) and cotrimoxazole exposure      <0.01    <0.01
On ART - On cotrimoxazole 667 4 0.06 (0.01-0.28) <0.01 0.05 (0.01-0.24) <0.01
Off ART - On cotrimoxazole 83 1 0.13 (0.01-1.25) 0.08 0.11 (0.01-1.08) 0.06
On ART - Off cotrimoxazole 332 17 0.58 (0.17-1.99) 0.38 0.58 (0.17-1.99) 0.39
Off ART - Off cotrimoxazole 35 3 1 - - 1 - -
Immunodeficiency for Age a      0.48    0.09
Severe 69 3 2.19 (0.65-7.39) 0.21 4.59 (1.32-15.98) 0.02
Moderate 106 3 1.40 (0.41-4.73) 0.59 2.09 (0.61-7.19) 0.24
No/Missing 942 19 1 - - 1 - -
Age      0.17    
<5 years 144 6 2.82 (0.98-8.13) 0.05   Not included  
[5-10[years 443 11 1.64 (0.66-4.09) 0.28    
≥10 years 530 8 1 - -    
Centres      <0.01    
CHU de Cocody 182 1 1 - -    
CHU de Yopougon 344 4 2.13 (0.24-19.08) 0.50   Not included  
CePReF 322 8 4.66 (0.58-37.30) 0.15    
CIRBA 212 2 1.74 (1.56-19.25) 0.65    
MTCT-Plus 57 10 35.20 (4.51-275.03) <0.01    
  1. N: number of children; n: number of malaria incident cases (only confirmed); IRR: incidence rate ratio; aIRR, adjusted incidence rate ratio; 95 % CI:95 % Confidence Interval. aUsing the 2010 WHO definition